The Lancet JUNE 23, 2023

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

Filip K. Knop, Vanita R. Aroda, Ricardo D. do Vale, et al.

Bottom Line

In this phase 3 trial, daily oral semaglutide 50 mg significantly reduced body weight compared with placebo over 68 weeks in adults with overweight or obesity without type 2 diabetes.

Key Findings

1. The estimated mean body weight change from baseline to 68 weeks was -15.1% in the oral semaglutide group compared to -2.4% in the placebo group (estimated treatment difference: -12.7 percentage points; 95% CI: -14.2 to -11.3; P<0.0001).
2. A weight reduction of at least 5% at week 68 was achieved by 85% of participants in the semaglutide group versus 26% in the placebo group (OR 12.6; 95% CI: 8.5–18.7; P<0.0001).
3. Weight loss milestones of at least 10%, 15%, and 20% were achieved significantly more frequently with semaglutide compared to placebo (P<0.0001 for all).
4. Gastrointestinal adverse events were more frequent in the oral semaglutide group (80%) compared to the placebo group (46%), primarily being mild to moderate in severity.

Study Design

Design
RCT
Double-Blind
Sample
667
Patients
Duration
68 wk
Median
Setting
Multicenter, international
Population Adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, without type 2 diabetes.
Intervention Oral semaglutide, escalated to 50 mg once daily.
Comparator Placebo once daily.
Outcome Percentage change in body weight from baseline to week 68 and achievement of weight reduction of at least 5% at week 68.

Study Limitations

The study enrolled a population predominantly consisting of females (74%), which may limit the generalizability of findings across different genders.
The 7-week off-treatment follow-up period may be insufficient to fully assess the long-term sustainability of weight loss post-discontinuation.
Higher gastrointestinal adverse event rates necessitate careful patient counseling and dose titration strategies in clinical practice.

Clinical Significance

This trial demonstrates that a high-dose oral formulation of semaglutide (50 mg) is an effective, once-daily therapeutic option for weight management in patients with overweight or obesity, offering an alternative to injectable GLP-1 receptor agonists for patients with specific administration preferences.

Historical Context

While once-weekly injectable semaglutide 2.4 mg (Wegovy) previously established a high standard for pharmacological weight management, the OASIS 1 trial explored whether a high-dose oral formulation could achieve comparable efficacy, addressing the clinical need for non-injectable options in this therapeutic class.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

How does the co-formulation with sodium salcaprozate (SNAC) allow a peptide like semaglutide to be absorbed orally, and what are the primary physiological mechanisms by which GLP-1 receptor agonists induce weight loss?

Key Response

Peptides are typically degraded by gastric acid and proteases. SNAC acts as an absorption enhancer by locally increasing pH to protect semaglutide from pepsin and promoting its transcellular absorption across the gastric epithelium. Weight loss is primarily achieved through central nervous system modulation of satiety and hunger in the hypothalamus, alongside delayed gastric emptying.

Resident
Resident

In clinical practice, what are the specific administration requirements for oral semaglutide 50 mg that must be communicated to patients to ensure efficacy, and how do the gastrointestinal side effects observed in OASIS 1 influence the titration schedule?

Key Response

Oral semaglutide must be taken on an empty stomach upon waking with no more than 120 mL of plain water, followed by at least a 30-minute fast to ensure absorption. In OASIS 1, dose escalation (starting at 3 mg and moving to 50 mg) was used to mitigate the high frequency of GI side effects (nausea, constipation, diarrhea) which are most prevalent during the titration phase.

Fellow
Fellow

Comparing the OASIS 1 results (oral 50 mg) to the STEP 1 trial (subcutaneous 2.4 mg), the weight loss percentages are remarkably similar (15.1% vs 14.9% estimated treatment policy). What pharmacological factors explain why a 50 mg oral dose is required to achieve parity with a 2.4 mg subcutaneous dose, and how should this influence the management of patients with malabsorptive conditions?

Key Response

The oral bioavailability of semaglutide is extremely low (approximately 0.4–1.0%), necessitated by the harsh gastric environment despite SNAC. This requires a much higher molar dose (50 mg daily vs 2.4 mg weekly). Patients with history of bariatric surgery or significant gastrointestinal motility disorders were excluded from the trial, suggesting caution and potentially prioritizing subcutaneous routes in those with altered gut anatomy or absorption.

Attending
Attending

OASIS 1 demonstrated significant weight loss, but the 'treatment policy estimand' showed a lower effect size than the 'trial product estimand' (15.1% vs 17.4%). How should this distinction inform your counseling of a patient who is hesitant about the long-term commitment to a daily high-dose oral peptide?

Key Response

The treatment policy estimand reflects real-world outcomes including those who stopped the drug, while the trial product estimand reflects the biological potential if taken perfectly. The attending must highlight that while the drug is highly effective, the 'real-world' 15% loss accounts for the ~13% discontinuation rate (mostly due to adverse events), emphasizing that persistence is key to achieving the higher efficacy figures.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

The OASIS 1 trial utilized a double-dummy design to maintain blinding. Critically evaluate the impact of this design on the assessment of patient-reported outcomes (PROs) and whether the high rate of gastrointestinal side effects in the treatment arm could have led to 'unblinding' by participants, potentially biasing the subjective weight-related quality of life scores.

Key Response

Since 80% of the treatment group experienced GI side effects compared to 46% of the placebo group, participants may have correctly guessed their assignment. This 'unblinding' effect can inflate PROs related to treatment satisfaction and perceived efficacy. Future trials might consider active placebos or sensitivity analyses that adjust for the presence of side effects when reporting subjective quality-of-life improvements.

Journal Editor
Journal Editor

Given the 68-week duration of OASIS 1, to what extent can we conclude that the weight loss had truly plateaued, and does the safety data provided allow for a robust assessment of rare but serious risks like pancreatitits or medullary thyroid carcinoma in a non-diabetic population?

Key Response

While the weight loss curve was flattening, some slope remained at week 68, suggesting maximum efficacy might require longer observation. Furthermore, for a 50 mg dose—nearly four times the highest approved T2DM dose—the sample size (N=667) is insufficient to exclude rare but serious GLP-1 associated risks, necessitating a call for larger post-marketing surveillance data in the editorial commentary.

Guideline Committee
Guideline Committee

The 2022 AHA/ACC/TOS and 2023 AACE guidelines emphasize GLP-1 RAs for obesity. How does the emergence of a 50 mg oral formulation change the hierarchy of recommendations currently dominated by subcutaneous semaglutide and tirzepatide, particularly regarding health equity and resource-limited settings?

Key Response

Current guidelines prioritize efficacy and metabolic co-morbidities. While oral semaglutide 50 mg offers a non-invasive alternative with similar efficacy to SQ semaglutide 2.4 mg, its daily dosing and strict fasting requirements may affect adherence. Guideline updates must now weigh the benefit of 'needle-free' options against the likely higher cost of goods for high-dose oral peptides and the potential for reduced efficacy if administration protocols are not strictly followed.

Clinical Landscape

Noteworthy Related Trials

2019

PIONEER 1 Trial

n = 703 · JAMA

Tested

Oral semaglutide (3, 7, or 14 mg daily)

Population

Adults with type 2 diabetes

Comparator

Placebo

Endpoint

Change in HbA1c from baseline to week 26

Key result: Oral semaglutide demonstrated superior reductions in HbA1c and body weight compared to placebo at all dose levels.
2021

STEP 1 Trial

n = 1,961 · NEJM

Tested

Subcutaneous semaglutide 2.4 mg once weekly

Population

Adults with overweight or obesity without diabetes

Comparator

Placebo

Endpoint

Percentage change in body weight from baseline to week 68

Key result: Participants receiving semaglutide had a mean change in body weight of -14.9% compared to -2.4% in the placebo group.
2023

OASIS 2 Trial

n = 1,429 · Lancet Diabetes Endocrinol

Tested

Oral semaglutide 50 mg once daily

Population

Adults with type 2 diabetes and overweight or obesity

Comparator

Placebo

Endpoint

Percentage change in body weight from baseline to week 68

Key result: Participants treated with 50 mg oral semaglutide achieved a significantly greater weight loss of -9.5% compared to -1.8% in the placebo group.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis